Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186420 | 0.83 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL12477212 | 0.80 | HCAR3 (0.57) | HCAR3HCAR2 | |
| SCHEMBL186474 | 0.80 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL691502 | 0.79 | HCAR3 (0.60) | HCAR3HCAR2 | |
| SCHEMBL18193683 | 0.79 | HCAR3 (0.74) | HCAR3HCAR2 | |
| SCHEMBL7230169 | 0.78 | HCAR3 (0.73) | HCAR3HCAR2 | |
| SCHEMBL13685154 | 0.78 | PTGS1 (0.43) | HCAR3HCAR2 | |
| SCHEMBL22047713 | 0.78 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL82675 | 0.77 | HCAR3 (0.68) | HCAR3HCAR2 | |
| SCHEMBL30403146 | 0.77 | HCAR3 (1.00) | HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | HCAR3 569/4885HCAR2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.